Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Administering BPC 157 without medical supervision can result in legal consequences and health risks
Tracking features may help users monitor their routines and identify patterns
This will lead to increased appetite and cravings for high-calorie foods
This product is: Not intended for human consumption
These studies confirm its safety for topical applications
Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use
US$ 20.87
US$ 28.22
US$ 21.97
